Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2282)	8/30/2013 8:49:31 PM
From: Clarksterh	Respond to of 2344

But what does it mean without a mechanism? If they have data showing that Red is correct, the vaccine is of considerable value. Pair the sucker with ipi, an ido inhibitor, anti-PD-1/PD-L1, etc. and get some near-term human experiments going..... FDA has never been as open to innovation as they are at the moment, particularly involving combo therapies for cancer. FWIW I agree with all of the above. And they would need no one but the FDA's easily obtained permission to do a proof of concept with ipi. The fact that haven't moved forward in an ipi combo probably says something - probably negative (like no confidence), but could be positive (in on-going negotiations with an anti-PD-1 provider)